---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-098843"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:31:21.352705+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eloxx submits IND for ELX-02 in Alport syndrome; Phase 2 data show remission in 1 of 3 patients

## Summary
- Submitted IND to FDA for ELX-02 to treat Alport syndrome with nonsense mutations.
- Phase 2 open-label trial: Patient 4401-02 achieved remission with UPCR improving from 1,646 to 850 mg/g during treatment.
- Two other patients (4401-01, 4402-01) did not achieve remission; UPCR increased post-treatment.
- Data show on-treatment remission in one patient, confirming drug activity.

## SEC filing metadata
- accession: 0001104659-23-098843
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465923098843/0001104659-23-098843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465923098843/tm2325683d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-098843
- JSON: https://secwatch.observer/filing/0001104659-23-098843.json
- Plain text: https://secwatch.observer/filing/0001104659-23-098843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.